Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update Meeting Abstract
| Authors: | Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; Vos, S. E.; Holte, H.; Linton, K. M.; Aqeel, A.; Wang, L.; Dinh, M.; Elliott, B.; Belada, D. |
| Abstract Title: | Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update |
| Meeting Title: | 2022 Lymphoma, Leukemia and Myeloma Congress |
| Journal Title: | American Journal of Hematology |
| Volume: | 97 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Oct 18-22 |
| Meeting Location: | New York, NY |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S31 |
| Language: | English |
| ACCESSION: | WOS:000866743000051 |
| PROVIDER: | wos |
| PUBMED: | 36227644 |
| DOI: | 10.1002/ajh.26736 |
| Notes: | Meeting Abstract: P-049 -- Source: Wos |
